Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain

J Med Chem. 2017 Jan 12;60(1):349-361. doi: 10.1021/acs.jmedchem.6b01422. Epub 2016 Dec 20.

Abstract

The large GTPase dynamin mediates membrane fission during clathrin-mediated endocytosis (CME). The aminopyrimidine compounds were reported to disrupt dynamin localization to the plasma membrane via the PH domain and implicate this mechanism in the inhibition of CME. We have used a computational approach of binding site identification, docking, and interaction energy calculations to design and synthesize a new library of aminopyrimidine analogues targeting site-2 of the pleckstrin homology (PH) domain. The optimized analogues showed low micromolar inhibition against both dynamin I (IC50 = 10.6 ± 1.3 to 1.6 ± 0.3 μM) and CME (IC50(CME) = 65.9 ± 7.7 to 3.7 ± 1.1 mM), which makes this series among the more potent inhibitors of dynamin and CME yet reported. In CME and growth inhibition cell-based assays, the data obtained was consistent with dynamin inhibition. CEREP ExpresS profiling identified off-target effects at the cholecystokinin, dopamine D2, histamine H1 and H2, melanocortin, melatonin, muscarinic M1 and M3, neurokinin, opioid KOP and serotonin receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding, Competitive
  • Carbon-13 Magnetic Resonance Spectroscopy
  • Cell Line, Tumor
  • Drug Screening Assays, Antitumor
  • Dynamin I / antagonists & inhibitors*
  • Enzyme Inhibitors / metabolism
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Mass Spectrometry
  • Pleckstrin Homology Domains / drug effects*
  • Proton Magnetic Resonance Spectroscopy
  • Pyrimidines / metabolism
  • Pyrimidines / pharmacology*

Substances

  • Enzyme Inhibitors
  • Pyrimidines
  • Dynamin I
  • pyrimidine